- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc stock price live, this page displays NASDAQ ABEO stock exchange data. View the ABEO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abeona Therapeutics Inc real time stock price chart below.
What Is the Abeona Therapeutics Inc Stock Price Today?
The Abeona Therapeutics Inc stock price today is 2,4200.
What Is the Stock Symbol for Abeona Therapeutics Inc?
The stock symbol for Abeona Therapeutics Inc is "ABEO."
What Stock Exchange Does Abeona Therapeutics Inc Trade On?
Abeona Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Abeona Therapeutics Inc a Good Stock to Buy?
Determining whether Abeona Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABEO quote. (ISIN: US00289Y2063)
What Is the Abeona Therapeutics Inc Stock Price Today?
The Abeona Therapeutics Inc stock price today is 2,4200.
What Is the Stock Symbol for Abeona Therapeutics Inc?
The stock symbol for Abeona Therapeutics Inc is "ABEO."
What Stock Exchange Does Abeona Therapeutics Inc Trade On?
Abeona Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Abeona Therapeutics Inc a Good Stock to Buy?
Determining whether Abeona Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABEO quote. (ISIN: US00289Y2063)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0900
2.4350
52 wk Range
2.0900
7.6500
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.09002.4350
52 wk Range
2.09007.6500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABEO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
15.5625
Upside
+543.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 8K Abeona Therapeutics Inc For: 9 November- Investing.com
Abeona reports Q3 Zevaskyn revenue of $13.5 million- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 15.5625
(+543.08% Upside)
Abeona Therapeutics Inc Earnings Call Summary for Q3/2026
- Abeona reported Q3 2026 EPS of -$0.08, beating consensus of -$0.18, but revenue of $13.49M missed estimates by 2.6%; stock fell 14.39% premarket.
- ZEVASKYN revenue rose 18% sequentially to $13.5M with 6 patients treated in Q3; company expanded treatment center network to 8 sites with 15 total patients.
- Management expects gross margins to reach 85-90% at full capacity; plans to expand manufacturing from 6 to 10 patients monthly by mid-2027.
- Acquired ABO-801 for eosinophilic esophagitis with phase III trial start planned mid-2027 and top-line results expected end of 2028; peak revenue potential over $750M.
- Company holds $134.9M cash as of Sept. 30 with $11.9M quarterly burn; manufacturing variability and planned Q4 biopsy pause present near-term execution risks.
Last Updated: 2026/11/09, 16:30
Read Full TranscriptEarnings
Latest Release
Nov 09, 2026
EPS / Forecast
-0,08 / -0,18
Revenue / Forecast
13,49M / 13,85M
Compare ABEO to Peers and Sector
Metrics to compare | ABEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −1.4x | −0.2x | |
PEG Ratio | 0.01 | −0.16 | 0.00 | |
Price/Book | 1.1x | 2.1x | 2.6x | |
Price / LTM Sales | 3.5x | 6.7x | 2.8x | |
Upside (Analyst Target) | - | 221.0% | 63.4% | |
Fair Value Upside | Unlock | 14.4% | 9.5% | Unlock |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Abeona Therapeutics (ABEO) Stock Price Today?
The Abeona Therapeutics stock price today is 2,4200 USD.
What Stock Exchange Does Abeona Therapeutics Trade On?
Abeona Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Abeona Therapeutics?
The stock symbol for Abeona Therapeutics is "ABEO."
What Is the Abeona Therapeutics Market Cap?
As of today, Abeona Therapeutics market cap is 137,7200M USD.
What Is Abeona Therapeutics's Earnings Per Share (TTM)?
The Abeona Therapeutics EPS (TTM) is -1,10.
When Is the Next Abeona Therapeutics Earnings Date?
Abeona Therapeutics will release its next earnings report on Mar 24, 2027.
From a Technical Analysis Perspective, Is ABEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Abeona Therapeutics Stock Split?
Abeona Therapeutics has split 4 times.
How Many Employees Does Abeona Therapeutics Have?
Abeona Therapeutics has 226 employees.
What is the current trading status of Abeona Therapeutics (ABEO)?
As of Nov 13, 2026, Abeona Therapeutics (ABEO) is trading at a price of 2,4200 USD, with a previous close of 2,2900 USD. The stock has fluctuated within a day range of 2,0900 USD to 2,4350 USD, while its 52-week range spans from 2,0900 USD to 7,6500 USD.
What Is Abeona Therapeutics (ABEO) Price Target According to Analysts?
The average 12-month price target for Abeona Therapeutics is 15,5625 USD, with a high estimate of 21 USD and a low estimate of 7.5 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +543,08% Upside potential.
What Is the ABEO Premarket Price?
ABEO's last pre-market stock price is 2,3591 USD. The pre-market share volume is 70 270,0000, and the stock has decreased by 0,0691, or 3,0200%.
What Is the ABEO After Hours Price?
ABEO's last after hours stock price is 2,3600 USD, the stock has decreased by -0,0600, or -2,4800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.